Literature DB >> 16282039

The use of opioids in the treatment of osteoarthritis: when, why, and how?

Jeremy L R Goodwin1, Jan J Kraemer, Zahid H Bajwa.   

Abstract

As life expectancy increases every decade, the incidence and prevalence of osteoarthritis (OA) also will increase. Despite progress in our knowledge of the pathophysiology of OA, the management of OA-mediated pain continues to challenge physicians. Concern regarding the cardiovascular effects of cyclooxygenase-2 inhibitors and the gastrointestinal and renal side effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in general has limited the use of these medications in the management of chronic non-cancer pain. Appropriately dosed and monitored use of opioids for OA pain, when more conservative methods have failed, has potentially fewer life-threatening complications associated with it than the more commonly and often less successfully employed pharmacotherapeutic approaches to care. When used as part of a multimodal approach to pain control, opioids are a safe and effective treatment for joint pain, including that of OA. Patients for whom NSAIDs are contraindicated, or for whom combined acetaminophen, tramadol, and NSAID therapy is ineffective, may be started on low-dose opioids and titrated as needed and tolerated. Patient education and informed consent, exercise, complementary medicine, and the use of a controlled substance agreement increases the likelihood of patient compliance with treatment guidelines, improving functional capacity and quality of life.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282039     DOI: 10.1007/s11916-005-0018-3

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  28 in total

Review 1.  Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials.

Authors:  Jan Magnus Bjordal; Anne Elisabeth Ljunggren; Atle Klovning; Lars Slørdal
Journal:  BMJ       Date:  2004-11-23

2.  Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States.

Authors:  R C Lawrence; C G Helmick; F C Arnett; R A Deyo; D T Felson; E H Giannini; S P Heyse; R Hirsch; M C Hochberg; G G Hunder; M H Liang; S R Pillemer; V D Steen; F Wolfe
Journal:  Arthritis Rheum       Date:  1998-05

3.  Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center.

Authors:  Niels Becker; Annemarie Bondegaard Thomsen; Alf Kornelius Olsen; Per Sjøgren; Per Bech; Jørgen Eriksen
Journal:  Pain       Date:  1997-12       Impact factor: 6.961

4.  Impact of arthritis and other rheumatic conditions on the health-care system--United States, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-05-07       Impact factor: 17.586

5.  Update of ACR guidelines for osteoarthritis: role of the coxibs.

Authors:  Thomas J Schnitzer
Journal:  J Pain Symptom Manage       Date:  2002-04       Impact factor: 3.612

6.  Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004.

Authors:  Theodore J Cicero; James A Inciardi; Edgar H Adams; Anne Geller; Edward C Senay; George E Woody; Alvaro Muñoz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-12       Impact factor: 2.890

Review 7.  Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids.

Authors:  S D Passik; H J Weinreb
Journal:  Adv Ther       Date:  2000 Mar-Apr       Impact factor: 3.845

Review 8.  Risk-benefit assessment of opioids in chronic noncancer pain.

Authors:  B Bannwarth
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

9.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.

Authors:  N V Chandrasekharan; Hu Dai; K Lamar Turepu Roos; Nathan K Evanson; Joshua Tomsik; Terry S Elton; Daniel L Simmons
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

10.  Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol).

Authors:  R J Flower; J R Vane
Journal:  Nature       Date:  1972-12-15       Impact factor: 49.962

View more
  3 in total

1.  Perforated peptic ulcer and short-term mortality among tramadol users.

Authors:  Marie L Tørring; Anders Riis; Steffen Christensen; Reimar W Thomsen; Peter Jepsen; Jens Søndergaard; Henrik T Sørensen
Journal:  Br J Clin Pharmacol       Date:  2007-10-08       Impact factor: 4.335

Review 2.  Arthritis and pain. Current approaches in the treatment of arthritic pain.

Authors:  Bruce L Kidd; Richard M Langford; Theresa Wodehouse
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

3.  Chronic non-cancer pain: Focus on once-daily tramadol formulations.

Authors:  Flaminia Coluzzi; Consalvo Mattia
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.